Trial
NCT03110575
12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Tonix Pharmaceuticals, Inc.
Collaborators
Premier Research
Condition
PTSD
Intervention
TNX-102 SL
Why stopped
Stopped early due to inadequate separation on primary efficacy endpoint in the lead-in HONOR study, TNX-CY-P301
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-06